(via NewsDirect)
He also highlights what he calls a significant improvement in margins and notes that much of the revenue growth came from product sales, indicating a shift away from development contracts.
Looking ahead, Basu suggests that Kromek's sectors remain strong, with advanced imaging benefiting from an ageing population's demand for better healthcare and the need for improved diagnostics. On the other side of the business, Basu is also upbeat on the prospects for Kromek's Chemical, Biological, Radiological and Nuclear (CBRN) arm due to increasing security demands driven by global political instabilities.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source